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ABSTRACT
Objective to provide an understanding of the role 
of common genetic variations in colorectal cancer 
(crc) risk, we report an updated field synopsis and 
comprehensive assessment of evidence to catalogue all 
genetic markers for crc (crcgene2).
Design We included 869 publications after 
parallel literature review and extracted data for 
1063 polymorphisms in 303 different genes. Meta- 
analyses were performed for 308 single nucleotide 
polymorphisms (SnPs) in 158 different genes with at 
least three independent studies available for analysis. 
Scottish, canadian and Spanish data from genome- wide 
association studies (gWaSs) were incorporated for the 
meta- analyses of 132 SnPs. to assess and classify the 
credibility of the associations, we applied the Venice 
criteria and Bayesian False- Discovery Probability (BFDP). 
genetic associations classified as ’positive’ and ’less- 
credible positive’ were further validated in three large 
gWaS consortia conducted in populations of european 
origin.
Results We initially identified 18 independent 
variants at 16 loci that were classified as ’positive’ 
polymorphisms for their highly credible associations with 
crc risk and 59 variants at 49 loci that were classified 
as ’less- credible positive’ SnPs; 72.2% of the ’positive’ 
SnPs were successfully replicated in three large gWaSs 
and the ones that were not replicated were downgraded 
to ’less- credible’ positive (reducing the ’positive’ variants 
to 14 at 11 loci). For the remaining 231 variants, which 
were previously reported, our meta- analyses found no 
evidence to support their associations with crc risk.
Conclusion the crcgene2 database provides an 
updated list of genetic variants related to crc risk by 
using harmonised methods to assess their credibility.
InTRODuCTIOn
Colorectal cancer (CRC) is one of the most 
commonly diagnosed malignancies and the 
leading cause of cancer deaths in the world, with 
1.65 million new cases and about 835 000 deaths 
in 2015.1 The global burden of CRC is expected 
to increase by 60%, with more than 2.2 million 
new cases and almost 1.1 million deaths occurring 
annually by 2030.2 The distribution of CRC global 
burden varies widely, with more than two- thirds 
Summary box
 What is already known on this subject?
 ► Colorectal cancer (CRC) is a global public 
health challenge. A large number of genetic 
association studies have been conducted 
to assess the potential correlation between 
common genetic variations and CRC risk.
 What are the new findings?
 ► Using an established framework for grading 
credibility of genetic associations, we classified 
14 independent variants at 12 loci (MUTYH, 
SMAD7, TERT, CDH1, RHPN2, BMP2, TGFB1 and 
common variants tagging loci at 8q24, 8q23.3, 
10p14, 11q23.1, 20p12.3) as highly credibly 
associated with CRC risk. A total of 63 variants 
at 52 loci were classified as ‘less- credible 
positive’ SNPs; variants of nine of these genes 
could be mostly highly prioritised for further 
investigation. For 231 variants previously 
reported to be associated with CRC, our meta- 
analyses found no evidence to support such 
associations.
 How might it impact on clinical practice in the 
foreseeable future?
 ► This database will be helpful for future research 
by promoting the investigation of these variants 
and corresponding genetic loci in populations 
other than of European origin, serving as a 
genetic basis for predicting risk estimates for 
population groups and providing candidate 
genes for further functional studies or gene- 
environment interaction studies.
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of all cases and about 60% of all deaths occurring in countries 
with a high or very high human development index, including 
Australia and New Zealand, Europe and North America, while 
incidence and mortality rates in Africa and South- Central Asia 
are relatively low.1 2 These geographic differences appear to be 
attributable to the differences in both environmental exposures 
and the background of genetically determined susceptibility.3
It is estimated that 15%–25% of CRC risk variance is attributed 
to inherited genetic factors, and the first- degree relatives of CRC 
patients have two to four times higher risk of developing CRC.4 5 
The inherited genetic risk of CRC can be partly accounted for 
by a combination of rare high- penetrance mutations and large 
numbers of common genetic variants each conferring small risk.6 
Although a number of highly penetrant mutations (eg, DNA 
mismatch repair genes, APC, SMAD4, LKB1/STK11, MUTYH) 
have been identified to influence CRC susceptibility with large 
effects, overall they account for only 2%–5% of incident CRC 
cases in the general population because these mutations are very 
rare.7–9 Candidate gene association studies have investigated the 
role of a large number of common genetic variants in CRC risk, 
but only a small number of them have been successfully repli-
cated in subsequent studies.10 11
In 2012 and 2014, we reported two independently conducted 
series of meta- analyses to systematically evaluate associations 
between CRC and common variants using data from candidate 
gene studies and genome- wide association studies (GWASs) and 
identified a number of promising genetic risk variants for CRC 
risk.10 11 Our first field synopsis (published in 2012) reported 
16 variants in 13 independent loci (MUTYH, MTHFR, SMAD7, 
8q24, 8q23.3, 11q23.1, 14q22.2, 1q41, 20p12.3, 20q13.33, 
3q26.2, 16q22.1, 19q13.1),10 and the second field synopsis 
(published in 2014) identified 8 additional variants in 5 inde-
pendent loci (APC, CHEK2, DNMT3B, MLH1, MUTYH) that 
were strongly associated with CRC.11 These two synopses used 
slightly different methodologies, in that the 2012 field synopsis 
only included variants reported in four or more studies in meta- 
analyses, whereas the 2014 included variants with three or more 
studies, and there were some differences in the criteria applied 
for the evidence appraisal.10 11
In this study, we aimed to perform an updated field synopsis for 
CRC risk by including the most recently published genetic asso-
ciation studies, by following established guidelines12 13 and using 
harmonised methods for evidence appraisal.14–16 We systemati-
cally captured all published genetic association data on CRC for 
meta- analyses and subsequently incorporated data from GWAS 
consortia for interrogation. This study provides an up- to- date 
and publicly available database for CRC genetics (CRCgene2) 
and presents these data within a defined statistical and causal 
inference framework to aid interpretation of the results.13 We 
aimed to provide new insights into the fundamental biological 
mechanisms involved in colorectal carcinogenesis.
MeTHODS
Literature search and data collection
To identify genetic association studies of CRC risk, we searched 
the Medline database via the Ovid gateway and the search terms 
comprising medical subject headings (MeSH) and keywords 
relating to colorectal neoplasms, the MeSH heading ‘genetic 
predisposition to disease’, and the keywords ‘gene$’ and ‘asso-
ciate$’ were applied to terms in the entire article. The latest 
literature search was performed on 21 November 2018. We 
screened the eligibility of retrieved publications in a three- step 
parallel review of title, abstract and full text by following the 
predefined inclusion and exclusion criteria. Thus, each eligible 
study evaluated the association between a polymorphic genetic 
variant (with minor allele frequency ≥0.01 in the reference 
panel of the 1000 genomes) and a sporadic CRC. Studies inves-
tigating only premalignant conditions such as adenomas, polyps 
or dysplastic tissue were excluded. Studies investigating heredi-
tary CRC syndromes, such as familial adenomatous polyposis, 
hereditary non- polyposis CRC, juvenile polyposis syndrome 
and Gardner’s syndrome; solely focusing on the progression 
or histological phenotype of CRC; or studies in animals; were 
excluded. Case- control, cohort and GWASs were included, while 
family- based studies were excluded. All included studies were 
published in English in a peer- reviewed journal; studies only 
reported as conference abstracts were excluded. Data from the 
eligible studies were abstracted into two standardised tables, 
including the key variables with regard to the study identifiers 
and context, study design and limitations, genotype information 
and outcome effects.
A list of genetic variants that were investigated in meta- analyses 
was summarised and data from three GWAS consortia (Scotland, 
Canada and Spain) were incorporated for meta- analyses, when 
the genotype data are available for the listed variants. In brief, the 
Study of CRC in Scotland (SOCCS) is a population- based case- 
control GWAS that includes 3417 cases and 3500 controls. The 
Assessment of Risk for Colorectal Tumors In Canada (ARCTIC) 
is a case- control GWAS database that includes 1231 cases and 
1240 controls. The population- based cohort study in Spain 
comprised two phases (EPICOLON I and EPICOLON II) adding 
up to 2000 cases and 2000 controls. Restricted candidate gene 
genotyping data were available from both phases and GWAS 
data were only accessible from 881 cases and 667 controls from 
phase 2.17 18 More details about these GWAS datasets are present 
in online supplementary text.
Statistical analysis
Meta- analysis was performed for genetic variants with data 
available from at least three independent studies. Summary 
crude ORs and 95% CI for allelic, recessive and dominant 
genetic models were calculated by applying either the fixed- 
effect model (Mantel- Haenszel method) or the random- effects 
model (DerSimonian- Laird method) in case of the existence of 
substantial heterogeneity. The Q statistic (with a threshold of p 
value <0.05) and I2 metric were calculated to quantify between- 
study heterogeneity. Funnel plot analysis with an Egger test was 
conducted to test for small study effects. We also estimated the 
statistical power of each meta- analysis based on the significance 
level of α=0.05, the effect sizes and the allele frequencies of 
genetic variants (an integral component of the Bayesian False- 
Discovery Probability (BFDP) analysis).19 All statistical analysis 
was conducted by using R software (R x64 3.1.0).
Credibility of the identified genetic associations
We first applied the BFDP19 and the Venice criteria12 13 to 
assess the credibility of any observed genetic associations with 
p<0.05 in at least one genetic model. We then validated these 
associations in three additional GWAS consortia: Genetics and 
Epidemiology of Colorectal Cancer Consortium (GECCO),20 
Colorectal Transdisciplinary Study (CORECT, https:// research. 
fhcrc. org/ peters/ en/ corect- study. html) and Colon Colorectal 
Cancer Family Registry (CFR).21 With meta- analysis of these 
three GWAS datasets, we validated the observed genetic associ-
ations using data from 58 131 CRC cases and 67 347 controls 
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Figure 1 Diagram of the study design. ARCTIC, Assessment of Risk 
for Colorectal Tumors In Canada; BFDP, Bayesian False- Discovery 
Probability; CFR, Colorectal Cancer Family Registry; CORECT, 
Colorectal Transdisciplinary Study; CRC, colorectal cancer; EPICOLON, 
Gastrointestinal Oncology Group of the Spanish Gastroenterological 
Association; GECCO, Genetics and Epidemiology of Colorectal Cancer 
Consortium; GWASs, genome- wide association studies; SOCCS, Study of 
CRC in Scotland.
(online supplementary text), and the statistical power of valida-
tion was estimated accordingly.
The BFDP assesses the noteworthiness of an observed associa-
tion. The BFDP was selected rather than the false- positive report 
probability (FPRP) because it uses more information, defines 
the noteworthiness threshold explicitly in terms of the costs of 
false discovery and non- discovery, and does not suffer from the 
inferential limitations identified for the FPRP.22 We calculated 
BFDP values at two levels of prior probability: a medium/low 
prior level (0.05 to 10−3), close to what would be expected for a 
candidate gene, and a very low prior level (10−4 to 10−6), close 
to what would be expected for a random SNP. A noteworthy 
threshold was defined as 0.2 based on the assumption that the 
cost of false discovery would be four times higher than that of 
false non- discovery.19
According to the Venice criteria, the credibility of associations 
is assessed for three aspects: the amount of evidence, the extent 
of replication and the protection from bias.12 13 We used statis-
tical power to assess the volume of evidence and a grade of A, 
B and C was assigned, respectively, when statistical power was 
greater than 80%, 50%–79% or less than 50%. The extent of 
replication was assessed by the measurement of heterogeneity (I2 
criterion), and a grade of A, B and C was assigned, respectively, 
when I2 was less than 25%, 25%–49% or greater than 50%.12 
For protection from bias, a complete assessment is difficult; 
instead, we considered the following aspects: (1) the phenotype 
definition was addressed by our inclusion criteria—namely that 
cases would have newly incident CRC; (2) genotyping error rates 
are generally low; (3) the criterion of replication across studies in 
part addresses potential concerns about variation in genotyping 
quality between studies; and (4) the magnitude of effect of popu-
lation stratification appears to be small in general.23
Genetic associations were then classified into four categories 
based on the following criteria. Associations were classified as 
‘positive’ if they: (1) were statistically significant at a p value 
level of 0.05 in at least two of the genetic models, (2) had a 
BFDP less than 0.20 at least at the p value level of 0.05, (3) 
had a statistical power greater than 80%, (4) had an I2 less than 
50%. A class of ‘less- credible positive’, with a less- stringent 
threshold, was assigned to the associations (1) that were statis-
tically significant at a p value threshold of 0.05 in at least one 
of the genetic models, but (2) their BFDP was greater than 0.20 
or their statistical power was between 50% and 79% or had an 
I2 greater than 50%. Associations with p value large than 0.05 
were further classified as ‘null’ or ‘negative’ by assessing if there 
are more than 5000 cases. After credibility assessment, genetic 
variants classified as ‘positive’ and ‘less- credible positive’ were 
sent to the CORECT coordinating centre to validate their asso-
ciations with CRC risk using additive, dominant and recessive 
models. At this stage, ‘positive’ associations that failed to be vali-
dated (at p<0.05) were downgraded to ‘less- credible positive’. A 
schematic diagram is shown in figure 1 to demonstrate datasets 
included in each phase of the analysis.
ReSuLTS
Literature search and data collection
A total of 20 900 citations were identified from literature search. 
Of these, 6770 (32.4%) papers were published after the search 
period of the most recent field synopsis (31 December 2012).11 
After eligibility screening, we finally included and extracted data 
from 869 publications (figure 2), reporting the association of 
CRC risk with 1063 polymorphisms in 303 different genes, of 
which 308 polymorphisms were reported in at least three inde-
pendent studies.
Meta-analyses
Meta- analyses were conducted for 308 polymorphisms in 158 
different loci with data available in three or more candidate 
or GWA studies (online supplementary table 1). On average, 
these meta- analyses were based on 6149 CRC cases (median; 
IQR=2301–7334) and 7337 controls (median; IQR=2809–
8885) originating from 8 (median; IQR=4–9) case–control 
studies. Data from the Scottish, Canadian and/ or Spanish GWAS 
were incorporated in the meta- analyses for 132 SNPs. Summary 
crude ORs and 95% CI for the allelic, dominant and recessive 
models are presented in table 1. Of the meta- analyses for 308 
polymorphisms (tagged at different 158 loci), a total of 77 SNPs 
(25.6%) (tagged in 61 different loci) were identified to have a 
nominally statistically significant association (p value <0.05) 
with CRC risk in at least one of the three genetic models and 
were eligible for credibility assessment using the BFDP19 (online 
supplementary tables 2–4) and the Venice criteria12 13 and for 
validation in the three (GECCO, CORECT and CCFR) GWAS 
consortia (online supplementary tables 5–7).
Credibility assessment indicated 18 variants (5.8% of the meta- 
analysed SNPs) tagging 16 loci (rs36053993 and rs34612342 
in MUTYH, rs2066847 in NOD2, rs12953717 and rs4464148 
in SMAD7, rs1569686 in DNMT3B, rs2736100 in TERT, 
rs9858822 in PPAR- gamma, rs1862748 in CDH1, rs7259371 in 
RHPN2, rs355527 in BMP2, rs1800469 in TGFB1, rs10505477 
in 8q24, rs16892766 in 8q23.3, rs3802842 in 11q23.1, 
rs961253 in 20p12.3, rs10795668 in 10p14, rs4951291 in 
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Figure 2 The distribution of included studies published from 1991 to 2018.
1q32.1) had the most credible associations with CRC risk and 
are therefore referred to as ‘positive’ SNPs (table 1, online 
supplementary tables 2–4). These findings are based on accrued 
data on 1224 to 43 652 cases and on 1381 to 60 883 controls, 
with a median of 17 100 cases per meta- analysis. The linkage 
disequilibrium (LD) between these ‘positive’ polymorphisms was 
checked pairwise using the Ensembl LD calculator with refer-
ence to the 1000 genomes: phase 3 CEU population and we 
found two pairs of SNPs (rs355527 and rs961253, rs12953717 
and rs4464148) with r2 >0.20 (online supplementary tables 8). 
The other 59 variants (19.2% of the meta- analysed SNPs) in 49 
loci with p value <0.05 were classified as ‘less- credible positive’ 
SNPs, given high heterogeneity, low statistical power or a high 
possibility of being false positive (BFDP >0.2) for their associ-
ation with CRC risk (table 2, online supplementary tables 2–4). 
The summary findings for ‘less- credible positive’ SNPs were 
based on accrued data on 246 to 51 730 CRC cases and on 399 
to 53 589 controls, with a median of at least 4287 CRC cases per 
meta- analysis.
Polymorphisms classified as either ‘positive’ or ‘less- credible 
positive’ SNPs were sent for validation in synthesised data from 
the GECCO, CORECT and CCFR consortia. Validation was 
only able to be performed for 68 out of 77 polymorphisms, 
as one ‘positive’ variant (rs34612342 in MUTYH [Y179C] 
gene) was dropped due to its low imputation quality in these 
GWASs; 5 ‘less- credible positive’ polymorphisms (in GSTT1, 
GSTM1, TP73, CHEK2 and CYP2E1) had no rs numbers; and 
3 polymorphisms (in TP53 and KRAS) were not available in 
these GWASs; therefore, they were not able to be validated. 
Of the 17 ‘positive’ SNPs sent for validation, 7 polymorphisms 
(41.2%) in 6 different loci (rs12953717 and rs4464148 in 
SMAD7, rs355527 in BMP2, rs10505477 in 8q24, rs961253 
in 20p12.3, rs16892766 in 8q23.3, rs3802842 in 11q23.1) 
reached a genome- wide statistical significance (p≤5×10−8) in 
at least one meta- analysis model and 6 polymorphisms (35.3%) 
in 6 different loci (rs7259371 in RHPN2, rs2736100 in TERT, 
rs10795668 in 10p14, rs36053993 in MUTYH, rs1862748 in 
CDH1 and rs1800469 in TGFB1) reached a nominally statis-
tical significance (p<0.05) in at least one meta- analysis model. 
However, the remaining 4 polymorphisms (23.5%) in 4 different 
loci (rs2066847 in NOD2, rs1569686 in DNMT3B, rs9858822 
in PPAR- gamma and rs4951291 in 1q32.1) failed in the GWAS 
validation of all genetic models (online supplementary tables 
5–7) and they were therefore downgraded to ‘less- credible 
positive’. Of the 51 ‘less- credible positive’ SNPs sent for valida-
tion, 2 polymorphisms (3.9%) in 2 different loci (rs6983267 in 
8q24 and rs1801155 in APC) reached a genome- wide statistical 
significance (p≤5×10−8) in at least one meta- analysis model 
and 11 polymorphisms (21.6%) in 11 different loci (rs1136410 
in PARP1, rs11568820 in VDR, rs1342387 in ADIPOR1, 
rs719725 in TPD52L3, rs20417 in PTGS2/COX2, rs2665802 in 
GH1, rs4803455 in TGFB1, rs7849 in SCD, rs8752 in HPGD, 
rs36053993 in MUTYH and rs928554 in ESR2) reached a nomi-
nally statistical significance (p<0.05) in at least one meta- analysis 
model, whereas the remaining 38 polymorphisms (74.5%) failed 
in the GWAS validation of all genetic models (online supplemen-
tary tables 5–7). Overall, 26 (33.8%) out of the 77 nominally 
significant polymorphisms tested via meta- analysis were success-
fully validated in these GWASs (p<0.05).
Funnel plots were produced for all ‘credible’ (online supple-
mentary figures 1–14) and ‘less- credible’ SNPs (online supple-
mentary figures 15–77) for their summary estimates in allelic 
model. Small study effects were reported for 2 (14.3%) of 
the 14 ‘positive’ polymorphisms (rs36053993 in MUTYH and 
rs4464148 in SMAD7) and for 10 (15.9%) of 63 ‘less- credible’ 
polymorphisms (rs1229984 in ADH1B, rs25487 in XRCC1, 
rs2240308 in AXIN2, rs1799750 in MMP1, rs1048943 in 
CYP1A1, rs373572 in RAD18, rs1800566 in NQ01, rs2066844 
in NOD2, rs2665802 in GH1, rs712 in KRAS). Therefore, their 
reported association with CRC risk should be interpreted with 
caution.
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The remaining 231 polymorphisms (75.0%) assessed in meta- 
analyses were reported to have no statistically significant associ-
ation (p>0.05) with CRC risk in all three genetic models (online 
supplementary table 9), based on accrued data on 192 to 21 929 
cases and 251 to 24 054 controls, with median of at least 4017 
cases per meta- analysis. Of them, 148 polymorphisms were clas-
sified as having negative associations with CRC risk because the 
number of cases was less than 5000 for which the null results 
could be due to limited statistical power, while another 83 SNPs 
with p>0.05 and the number of cases>5000 were classified as 
null variants with adequate statistical power (online supplemen-
tary table 9).
DISCuSSIOn
This systematic, comprehensive field synopsis of genetic associa-
tion studies on CRC updates the two previous field synopses10 11 
with application of harmonised methods for evidence appraisal 
and further validation of the identified genetic associations in 
three GWAS consortia. Specifically, we extracted and collated 
data for 1063 polymorphisms in 303 different genes from 869 
publications and performed up- to- date meta- analyses for 308 
variants in 158 different genes that had data from at least three 
independent studies available for analysis. After credibility assess-
ment and validation, we identified a total of 12 genetic loci cred-
ibly associated with CRC risk, of which 6 loci (MUTYH, SMAD7, 
8q24, 8q23.3, 11q23.1, 20p12.3) were also classified as credibly 
associated with CRC risk in the previous field synopses and the 
other 6 loci (TGFB1, TERT, CDH1, RHPN2, BMP2 and 10p14) 
are novel findings as they have not been assessed or reported as 
credible risk loci in the previous field synopses.
We note that a synopsis was undertaken of literature on 
genetic associations with CRC published in the period 2012–
2017.24 Our analysis differs from that study, in that it includes 
and updates data from our previous field synopses,10 11 includes 
data from three GWA studies in the meta- analysis and further 
validates the findings in three GWA consortia.
Similar to our previous field synopses,10 11 the present study 
reported two SNPs at 8q24 locus (rs6983267 and rs10505477) 
with strong evidence supporting significant associations with 
CRC risk and with these associations further replicated in three 
GWAS consortia. In biopsies of the rectum, sigmoid colon and 
cecum mucosa, proliferation has been reported to be higher 
among homozygotes for the risk alleles of the rs6983267 and 
rs10505477 variants compared with those with other genotypes 
in the general population.25 The rs6983267 variant has been 
assessed as having a highly credible association with colorectal 
adenomas.26 27 In fine- mapping and bioinformatic analysis 
performed within the GECCO- CCFR consortia, the rs6983267 
variant was appraised as having a strong functional evidence.28 
The rs6983267 may be a somatic target in CRC29 and may be 
associated with enhanced responsiveness to Wnt signalling.30 
Furthermore, rs6983267 has also been found to be associated 
with other types of cancer, including prostate cancer.31–33 Inter-
action with the MYC proto- oncogene has been controversial,34–37 
but in functional studies in cell lines, interaction between 
enhancer elements in the 8q24 locus and the MYC promoter, via 
transcription factor Tcf-4 binding and allele- specific regulation 
of MYC expression, has been demonstrated.38 Expression levels 
of one of these, CARLo-5, in normal colon tissue have been 
found to be statistically significantly correlated with rs6983267, 
and chromosome conformation capture analysis of genomic 
DNA from CRC- derived cell lines provided evidence of physical 
interaction between the active regulatory region of the CARLo-5 
promoter and the MYC enhancer region.39 Since the end of our 
search period (21 November 2018), an analysis of GWAS data 
on 22 775 cases and 47 731 controls from 14 studies in East 
Asia detected a genome- wide significant association with the 
rs6983267 variant.40 In addition, in a combined meta- analysis 
of up to 58 131 cases and 67 347 controls from the GECCO, 
CORECT and CCFR consortia, in which imputed variants from 
a whole- genome sequencing analysis and Haplotype Refer-
ence Consortium panel variants were included, analysis in the 
8q24.21 region conditioned on the rs6983267 and rs7013278 
variants identified a genome- wide significant association with 
the rs4313119.41
Two genetic polymorphisms (rs12953717 and rs4464148) 
tagging in SMAD7 were identified to be associated with CRC 
with highly credible evidence. Associations with rs12953717 
and rs4464148 were successfully validated in the three 
GWAS consortia. In fine- mapping and bioinformatics analysis 
performed within the GECCO- CCFR consortia, rs4464148 
was appraised as having less strong functional evidence than the 
highly correlated rs9932005 variant, which is located within 5 kb 
away.28 The SMAD7 protein is an inhibitor for the TGF-ß signal-
ling pathway.42 43 There were highly credible associations with 
the rs1862748 (tagging CDH1), rs355527 (BMP2), rs961253 
(BMP2) and rs7259371 (RHPN2) variants, which are TGF-ß 
related, and replicated in the data from the GWAS consortia. In 
the recent East Asian analysis, the association with the rs961253 
(BMP2) variant was replicated, as well as additional variants of 
SMAD7 (rs7229639, rs4939827), CDH1 (rs9929218), BMP2 
(rs4813802) and RHPN2 (rs10411210).40 In the analysis from 
the GECCO, CORECT and CCFR consortia, conditioned on 
the rs4813802 and rs189583 variants of BMP2 as well as each 
other, novel associations with the BMP2 variants rs28488 and 
rs994308 were detected.41
Additionally, two variants (rs34612342 and rs36053993) 
tagging the MUTYH gene were highly credibly associated with 
increased CRC risk, of which rs36053993 was validated in the 
three GWAS consortia data, while rs34612342 was not tested 
due to its poor imputation quality. The MUTYH gene is known 
to be involved in the dysfunction of base- excision repair, which is 
the major pathway for repairing oxidative damage. This biolog-
ical pathway in which the MUTYH gene is involved contrib-
utes to the development of multiple colorectal adenomas and 
carcinomas (MUTYH- associated polyposis (MAP) syndrome).44 
In our analysis, the p values were nominally significant for all 
models for the rs34612342 variant and for the allelic and domi-
nant models for the rs36053993 variant. For the former variant, 
the magnitude of effect was greatest for the recessive model, 
although with wide CIs, which is intriguing as MAP, in which 
highly penetrant mutations are implicated, and is inherited in an 
autosomal recessive manner.45
Highly credible associations were also reported for four vari-
ants tagging four different genes that are involved in inflamma-
tion or immune response. First, a positive association with the 
rs3802842 variant in the 11q23.1 was identified for CRC risk 
and this association was replicated in the data from the GWAS 
consortia and in the recent East Asian analysis.40 Fine- mapping 
and bioinformatics analysis performed within the GECCO- 
CCFR consortia support this variant with strong functional 
evidence.28 Fine mapping identified two genes COLCA1 and 
COLCA2 arranged on opposite strands and sharing a regulatory 
region containing rs3802842.46 It is reported that carrying the 
risk allele of rs3802842 is associated with the expression levels 
of COLCA1 and COLCA2, which is further correlated with 
lymphocyte infiltration of colonic lamina propia. Further, in an 
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expression quantitative trait locus analysis in colorectal tissue, 
there were signals for COLCA1 and COLCA2.47 The polymor-
phism rs10795668 in 10p14 locus tagging GATA3 gene was 
reported with a highly credible association with CRC, and this 
association was further replicated in the GWAS consortia and 
in the recent East Asian analysis.40 However, in fine- mapping 
and bioinformatics analysis, this variant presents with weak 
functional evidence.28 Another less- credible positive association 
with the rs9858822 variant of PPARγ was identified; however, 
this association was not replicated in the GWAS consortia. Bioin-
formatics analysis showed that PPARγ and its ligands have been 
found to block proinflammatory genes in colon cancer cell lines, 
activated macrophages and monocytes.48 PPARγ is also involved 
in lipid metabolism, adipocyte differentiation, and glucose 
homeostasis and insulin sensitivity.48 A less- credible positive 
association also reported one variant (rs2066847) in NOD2 
gene; however, this association was not replicated. Evidence 
from experimental studies in mice investigating the role of Nod2 
in colorectal tumour risk has also been inconsistent.49–51 The 
recent analyses in East Asia,40 the GECCO, CORECT and CCFR 
consortia41 and of five UK studies and a further 10 from the 
COGENT consortium47 identified new associations in the major 
histocompatibility region.
The remaining two variants with highly credible associa-
tions with CRC risk included rs2736100 tagging TERT and 
rs16892766 at 8q23.3 tagging EIF3H. These variants were all 
validated in the GWAS consortia datasets. Fine- mapping and 
bioinformatics analysis performed within the GECCO- CCFR 
consortia supported these variants with strong functional 
evidence, for which polymorphism rs2736100 in TERT gene 
has been reported to be associated with telomere length and 
the risk of different types of cancer and chronic diseases other 
than cancer.52 For the association with the rs16892766 variant 
at 8q23.3 tagging EIF3H, another variant rs16888589 was 
previously reported with the lowest p value for the association 
with CRC in this locus.25 Functional analysis and chromosome 
conformation capture analysis in CRC cell lines have found that 
the genomic region harbouring rs16888589 increases EIF3H 
expression,53 but analysis of expression quantitative trait loci 
around rs16892766 suggested that UTP23 rather than EIF3H 
is the target of genetic variation associated with CRC in this 
region.54
The less credible associations with 63 variants of 52 genes 
involved the following pathways—adhesion (AXIN2, MMP1); 
alcohol metabolism (ADH1B); angiogenesis (VEGF); blood clot-
ting (SERPINE1); DNA repair (CHEK2, ERCC5, MSH2, MSH3, 
PARP1, RAD18, XPC, XRCC1); hormone metabolism (ESR2, 
GH1, PGR); inflammation and immune response (CRP, HPGD, 
PTGS2/COX2); inhibition of cell growth (CCND1, EGF, TGFB1); 
iron metabolism (HFE); lipid metabolism (ADIPOQ, ADIPOR1, 
LIPC, SCD); one- carbon metabolism (MTHFR, MTFD1, MTRR); 
substrate metabolism (ABCB1; CYP1A1, CYP2C9, CYP2E1, 
GSTM1, GSTT1, NAT2, NQ01); tumour suppression (ARLTS1, 
miR, TP73); vitamin D metabolism (VDR)—common low pene-
trance variants at 1q32.1 (rs4951039, LINC00303) and 9p24 
(rs719725); and the common rs1801155 (I1307K) variant of 
APC, for which large numbers of rare variants have been iden-
tified,55 and rs63750447 (V384D) variant of MLH1, for which 
rare variants confer a high risk of Lynch syndrome.56 These vari-
ants were classified as less- credible SNPs because of either the 
substantial heterogeneity or the high possibility of false positive; 
however, we would like to highlight a number of less- credible 
genetic loci (PARP1, MYC, VDR, ADIPOR1, APC, PTGS2/COX2, 
SCD, HPGD and ESR2), which were replicated in the GWAS 
data and for which their linked pathways are worthy of further 
investigation in future studies.
Updating field synopses is challenging because genetic analysis 
is such a fast- moving field. Recent trends highlighted by three 
articles published since we completed our search in November 
2018 include the extension of consortia to increase statistical 
power to detect and replicate associations,47 the investigation 
of populations other than of European origin,40 and the use of 
whole- genome sequencing and more comprehensive reference 
panels to extend the range of genetic variants considered to 
include those that are rare or of low frequency.41 These three 
articles have added new loci for CRC susceptibility and indi-
cate that most of the risk loci previously associated with CRC 
in populations of European origin are also associated with CRC 
risk in East Asian populations.
We checked whether the 14 variants we classified as ‘highly 
credible’ were replicated in the paper of Law et al.47 For one 
variant, rs34612342 MUTYH, there was poor imputation 
quality. However, as there was no satisfactory proxy for this, 
we report the available information, which supported the asso-
ciation (p=0.029). All the remaining 13 variants had p values 
for association less than 5.0×10−5 with no more than moderate 
heterogeneity. Such an empirical comparison was not appro-
priate with the data of Huyghe et al41 because of the consider-
able overlap of included participants.
In summary, we have conducted a comprehensive study to 
capture and meta- analyse all SNP data for common genetic 
variants. The analysis clearly identifies 14 variants at 12 loci for 
which there is robust evidence of their impact on CRC risk, 63 
variants at 52 loci for which further evidence through interna-
tional collaboration should be generated and 231 variants for 
which the overall evidence does not support any association 
with CRC risk. With increasing availability of data from multiple 
SNPs, it is clear that studies to test associations must achieve 
very high levels of statistical stringency. Nonetheless, the analysis 
here provides a resource for mining available data and puts into 
context the sample sizes required for the identification of true 
associations for common genetic variants. Future resequencing 
studies are expected to identify rarer variants (eg, prevalence 
0.05%–5%) with intermediate or perhaps even large effects, 
and GWAS of structural variation will likely identify deletions, 
amplifications and other copy number variations that may also 
influence CRC risk.6 This study highlights a number of common 
genetic variants that could be incorporated into genetic risk- 
prediction algorithms as further risk factors are identified and 
highlights the loci at which further research effort should be 
targeted. All data are available from the CRCgene2 database.
Author affiliations
1School of epidemiology and Public Health, Faculty of Medicine, University of 
Ottawa, Ottawa, Ontario, canada
2centre for global Health, Usher institute, the University of edinburgh, edinburgh, 
UK
3Department of epidemiology, college of Preventive Medicine, third Military Medical 
University, chongqing, chongqing, china
4colon cancer genetics group, cancer research UK edinburgh centre and 
Medical research council Human genetics Unit, Medical research council 
institute of genetics & Molecular Medicine, the University of edinburgh, 
edinburgh, UK
5Jockey club School of Public Health and Primary care, the chinese University of 
Hong Kong, Shenzhen, Hong Kong
6gastroenterology Department, institut D’investigacions Biomèdiques august Pi i 
Sunyer (iDiBaPS), Hospital clínic de Barcelona, Universitat de Barcelona, centro 
de investigación Biomédica en red de enfermedades Hepáticas y Digestivas 
(ciBereHD), Barcelona, Spain
7Fundación Pública galega de Medicina Xenómica, grupo de Medicina Xenómica, 
Santiago de compostela, Spain; instituto de investigación Sanitaria de Santiago 
 o
n
 D
ecem
ber 12, 2019 at University of Edinburgh. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2019-319313 on 9 December 2019. Downloaded from 
11Montazeri Z, et al. Gut 2019;0:1–12. doi:10.1136/gutjnl-2019-319313
GI cancer
(iDiS), centro de investigación Biomédica en red de enfermedades raras (ciBerer), 
Santiago de compostela, Spain
8leeds institute of cancer and Pathology, University of leeds, leeds, UK
9centre for epidemiology and Biostatistics, Melbourne School of Population and 
global Health, the University of Melbourne, Melbourne, Victoria, australia
10colorectal Oncogenomics group, genetic epidemiology laboratory, Department of 
Pathology, the University of Melbourne, Parkville, Victoria, australia
11genetic Medicine and Family cancer clinic, the royal Melbourne Hospital, Parkville, 
Victoria, australia
12center for gastrointestinal Biology and Disease, University of north carolina, 
chapel Hill, north carolina, USa
13Department of clinical genetics, Karolinska University Hospital, Stockholm, Sweden
14Department of Molecular Medicine and Surgery, Karolinska institutet, Stockholm, 
Sweden
15Division of Human nutrition, Wageningen University and research, Wageningen, 
the netherlands
16University of Southern california, Preventative Medicine, los angeles, california, 
USa
17cancer research UK edinburgh centre, Medical research council institute of 
genetics and Molecular Medicine, the University of edinburgh, edinburgh, UK
18Division of epidemiology, Vanderbilt University School of Medicine, nashville, 
tennessee, USa
Twitter Susan M Farrington @ccgg_edinburgh
Acknowledgements et is supported by a cancer research UK career 
Development Fellowship (c31250/a22804). SOccS: the work was supported by 
Programme grant funding from cancer research UK (c348/a12076) and by funding 
for the infrastructure and staffing of the edinburgh crUK cancer research centre. 
this work was also funded by a grant to MgD as Project leader with the Mrc 
Human genetics Unit centre grant (U127527202 and U127527198 from 1/4/18). 
We are grateful to all who contribute to recruitment, data collection and data 
curation for the Study of colorectal cancer in Scotland studies. We acknowledge 
that these studies would not be possible without the patients and controls and 
their families. We acknowledge the expert support on sample preparation from the 
genetics core of the edinburgh Wellcome trust clinical research Facility. arctic: 
arctic was funded by the canadian institutes of Health research (ciHr) team in 
interdisciplinary research on colorectal cancer (ctP-79845); a ciHr pilot project 
grant in colorectal cancer screening (200509ccS-152119- ccS- ceca-102806); the 
cancer risk evaluation (care) Program grant from the canadian cancer Society 
research institute (18001). ePicOlOn: We are sincerely grateful to all patients, the 
Spanish national Dna Bank (BnaDn) and Biobank of Hospital clínic–iDiBaPS. SnP 
genotyping services were provided by the Spanish ’centro nacional de genotipado’ 
(cegen- iSciii). this work was supported by grants from Fondo de investigación 
Sanitaria/FeDer (Pi17/00878, Pi17/00509), Fundación científica de la asociación 
española contra el cáncer (gcB13131592caSt), PeriS (Slt002/16/00398, 
generalitat de catalunya), cerca Programme (generalitat de catalunya) and 
agència de gestió d’ajuts Universitaris i de recerca (generalitat de catalunya, 
grPre 2017Sgr21, grc 2017Sgr653). ciBereHD and ciBerer are funded by 
the instituto de Salud carlos iii. this article is based upon work from cOSt action 
ca17118, supported by cOSt (european cooperation in Science and technology, 
www. cost. eu). this work was also supported by grant U01 ca167551 from the 
national cancer institute and through cooperative agreements with the following 
colon cancer Family registry sites: australasian colorectal cancer Family registry 
(U01 ca074778 and U01/U24 ca097735); Ontario Familial colorectal cancer 
registry (U01/U24 ca074783); and Seattle colorectal cancer Family registry (U01/
U24 ca074794). the genome- wide association studies (gWaS) were supported by 
grants U01 ca122839, r01 ca143237 and U19 ca148107.
Contributors Jl, WZ, et and Hc conceived the study; Jl, WZ, et, Hc, ZM and Xl 
designed it; ZM, Xl, et, Jl and Hc wrote the article with input from other authors; 
ZM, Xl, cn, Mt and VS undertook data manipulations and statistical analysis; ZM, 
Xl, cn, XMa, XMeng, YH and YB undertook the literature review and coordinated 
and/or undertook related abstraction, handling and curation of the data; SM, Sc- B, 
cr- P, cF- r, acarracedo, acastells, DB, MaJ, tOK, al, FJBvD, aW, SMF and MgD 
provided access to gWaS data. Hc, et, WZ and Jl are joint corresponding authors.
Funding the authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not- for- profit sectors.
Competing interests none declared.
Patient consent for publication not required.
Provenance and peer review not commissioned; externally peer reviewed.
Data availability statement all data relevant to the study are included in the 
article or uploaded as supplementary information.
Open access this is an open access article distributed in accordance with the 
creative commons attribution 4.0 Unported (cc BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
ORCID iDs
ceres Fernández- rozadilla http:// orcid. org/ 0000- 0001- 7330- 4804
Daniel Buchanan http:// orcid. org/ 0000- 0003- 2225- 6675
evropi theodoratou http:// orcid. org/ 0000- 0001- 5887- 9132
Wei Zheng http:// orcid. org/ 0000- 0003- 1226- 070X
Julian little https:// orcid. org/ 0000- 0001- 5026- 5531
RefeRences
 1 Fitzmaurice c, allen c, Barber rM, et al. global, regional, and national cancer 
incidence, mortality, years of life lost, years lived with disability, and Disability- 
adjusted life- years for 32 cancer groups, 1990 to 2015: a systematic analysis for the 
global burden of disease study. JAMA Oncol 2017;3:524–48.
 2 Ferlay J, Soerjomataram i, ervik M, et al. GLOBOCAN 2012 V1. 0, cancer incidence 
and mortality worldwide: IARC CancerBase No. 11. lyon, France: international agency 
for research on cancer, 2013.
 3 Huhn S, Pardini B, naccarati a, et al. ancestral susceptibility to colorectal cancer. 
Mutagenesis 2012;27:197–204.
 4 Muñoz M, Pong- Wong r, canela- Xandri O, et al. evaluating the contribution of 
genetics and familial shared environment to common disease using the UK Biobank. 
Nat Genet 2016;48:980–3.
 5 graff re, Möller S, Passarelli Mn, et al. Familial risk and heritability of colorectal 
cancer in the nordic twin study of cancer. Clinical Gastroenterology and Hepatology 
2017;15:1256–64.
 6 tenesa a, Dunlop Mg. new insights into the aetiology of colorectal cancer from 
genome- wide association studies. Nat Rev Genet 2009;10:353–8.
 7 de la chapelle a. genetic predisposition to colorectal cancer. Nat Rev Cancer 
2004;4:769–80.
 8 Jasperson KW, tuohy tM, neklason DW, et al. Hereditary and familial colon cancer. 
Gastroenterology 2010;138:2044–58.
 9 lung MS, trainer aH, campbell i, et al. Familial colorectal cancer. Intern Med J 
2015;45:482–91.
 10 theodoratou e, Montazeri Z, Hawken S, et al. Systematic meta- analyses and field 
synopsis of genetic association studies in colorectal cancer. J Natl Cancer Inst 
2012;104:1433–57.
 11 Ma X, Zhang B, Zheng W. genetic variants associated with colorectal cancer risk: 
comprehensive research synopsis, meta- analysis, and epidemiological evidence. Gut 
2014;63:326–36.
 12 ioannidis JP, Boffetta P, little J, et al. assessment of cumulative evidence on genetic 
associations: interim guidelines. Int J Epidemiol 2008;37:120–32.
 13 Khoury MJ, Bertram l, Boffetta P, et al. genome- Wide association studies, field 
Synopses, and the development of the knowledge base on genetic variation and 
human diseases. Am J Epidemiol 2009;170:269–79.
 14 allen nc, Bagade S, McQueen MB, et al. Systematic meta- analyses and field synopsis 
of genetic association studies in schizophrenia: the Szgene database. Nat Genet 
2008;40:827–34.
 15 Bertram l, McQueen MB, Mullin K, et al. Systematic meta- analyses of alzheimer 
disease genetic association studies: the alzgene database. Nat Genet 
2007;39:17–23.
 16 chatzinasiou F, lill cM, Kypreou K, et al. comprehensive field synopsis and systematic 
meta- analyses of genetic association studies in cutaneous melanoma. JNCI Journal of 
the National Cancer Institute 2011;103:1227–35.
 17 abulí a, Bessa X, gonzález Jr, et al. Susceptibility genetic variants associated 
with colorectal cancer risk correlate with cancer phenotype. Gastroenterology 
2010;139:788–96.
 18 Fernandez- rozadilla c, cazier J- B, tomlinson iP, et al. a colorectal cancer genome- 
wide association study in a Spanish cohort identifies two variants associated with 
colorectal cancer risk at 1p33 and 8p12. BMC Genomics 2013;14:55.
 19 Wakefield J. a Bayesian measure of the probability of false discovery in genetic 
epidemiology studies. The American Journal of Human Genetics 2007;81:208–27.
 20 Fehringer g, Kraft P, Pharoah PD, et al. cross- cancer genome- wide analysis of lung, 
ovary, breast, prostate, and colorectal cancer reveals novel pleiotropic associations. 
Cancer Res 2016;76:5103–14.
 21 newcomb Pa, Baron J, cotterchio M, et al. colon cancer family registry: an 
international resource for studies of the genetic epidemiology of colon cancer. Can 
Epidemiol Biomark Prev 2007;16:2331–43.
 22 lucke JF. a critique of the false- positive report probability. Genet Epidemiol 
2009;33:145–50.
 23 Freedman Ml, reich D, Penney Kl, et al. assessing the impact of population 
stratification on genetic association studies. Nat Genet 2004;36:388–93.
 24 Wen J, Xu Q, Yuan Y. Single nucleotide polymorphisms and sporadic colorectal 
cancer susceptibility: a field synopsis and meta- analysis. Cancer Cell Int 
2018;18:155.
 o
n
 D
ecem
ber 12, 2019 at University of Edinburgh. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2019-319313 on 9 December 2019. Downloaded from 
12 Montazeri Z, et al. Gut 2019;0:1–12. doi:10.1136/gutjnl-2019-319313
GI cancer
 25 Yang B, thyagarajan B, gross MD, et al. no evidence that associations of incident, 
sporadic colorectal adenoma with its major modifiable risk factors differ by 
chromosome 8q24 region rs6983267 genotype. Mol Carcinog 2014;53:e193–200.
 26 Montazeri Z, theodoratou e, nyiraneza c, et al. Systematic meta- analyses and field 
synopsis of genetic association studies in colorectal adenomas. Int J Epidemiol 
2016;45:186–205.
 27 abulí a, castells a, Bujanda l, et al. genetic variants associated with colorectal 
adenoma susceptibility. PLoS One 2016;11:e0153084.
 28 Du M, Jiao S, Bien Sa, et al. Fine- Mapping of common genetic variants associated 
with colorectal tumor risk identified potential functional variants. PLoS One 
2016;11:e0157521.
 29 tuupanen S, niittymaki i, nousiainen K, et al. allelic imbalance at rs6983267 
suggests selection of the risk allele in somatic colorectal tumor evolution. Cancer Res 
2008;68:14–17.
 30 tuupanen S, turunen M, lehtonen r, et al. the common colorectal cancer 
predisposition SnP rs6983267 at chromosome 8q24 confers potential to enhanced 
Wnt signaling. Nat Genet 2009;41:885–90.
 31 Yeager M, Orr n, Hayes rB, et al. genome- Wide association study of prostate cancer 
identifies a second risk locus at 8q24. Nat Genet 2007;39:645–9.
 32 thomas g, Jacobs KB, Yeager M, et al. Multiple loci identified in a genome- wide 
association study of prostate cancer. Nat Genet 2008;40:310–5.
 33 eeles ra, Kote- Jarai Z, giles gg, et al. Multiple newly identified loci associated with 
prostate cancer susceptibility. Nat Genet 2008;40:316–21.
 34 Pomerantz MM, ahmadiyeh n, Jia l, et al. the 8q24 cancer risk variant 
rs6983267 shows long- range interaction with Myc in colorectal cancer. Nat Genet 
2009;41:882–4.
 35 cicek MS, Slager Sl, achenbach SJ, et al. Functional and clinical significance of 
variants localized to 8q24 in colon cancer. Cancer Epidemiology Biomarkers & 
Prevention 2009;18:2492–500.
 36 Prokunina- Olsson l, Hall Jl. no effect of cancer- associated SnP rs6983267 in the 
8q24 region on co- expression of myc and tcF7l2 in normal colon tissue. Mol Cancer 
2009;8:96.
 37 Wright JB, Brown SJ, cole MD. Upregulation of c- myc in cis through a large chromatin 
loop linked to a cancer risk- associated single- nucleotide polymorphism in colorectal 
cancer cells. Mol Cell Biol 2010;30:1411–20.
 38 Sotelo J, esposito D, Duhagon Ma, et al. long- range enhancers on 8q24 regulate 
c- myc. Proc Natl Acad Sci U S A 2010;107:3001–5.
 39 Kim t, cui r, Jeon Y- J, et al. long- range interaction and correlation between Myc 
enhancer and oncogenic long noncoding rna carlo-5. Proc Natl Acad Sci U S A 
2014;111:4173–8.10.1073/pnas.1400350111
 40 lu Y, Kweon S- S, tanikawa c, et al. large- Scale genome- wide association study of 
east asians identifies loci associated with risk for colorectal cancer. Gastroenterology 
2019;156:1455–66.
 41 Huyghe Jr, Bien Sa, Harrison ta, et al. Discovery of common and rare genetic risk 
variants for colorectal cancer. Nat Genet 2019;51:76–87.
 42 loh YH, Mitrou Pn, Wood a, et al. SMaD7 and MgMt genotype variants and cancer 
incidence in the european Prospective investigation into cancer and nutrition (ePic)- 
norfolk Study. Cancer Epidemiol 2011;35:369–74.
 43 Stolfi c, Marafini i, De Simone V, et al. the dual role of Smad7 in the control of cancer 
growth and metastasis. Int J Mol Sci 2013;14:23774–90.
 44 grover S, Kastrinos F, Steyerberg eW, et al. Prevalence and phenotypes of aPc 
and MUtYH mutations in patients with multiple colorectal adenomas. JAMA 
2012;308:485–92.
 45 nielsen M, lynch H, infante e, et al. MUTYH- Associated polyposis. Seattle: University 
of Washington, 2015.
 46 Peltekova VD, lemire M, Qazi aM, et al. identification of genes expressed by immune 
cells of the colon that are regulated by colorectal cancer- associated variants. 
International Journal of Cancer 2014;134:2330–41.
 47 law PJ, timofeeva M, Fernandez- rozadilla c, et al. association analyses identify 31 
new risk loci for colorectal cancer susceptibility. Nat Commun 2019;10:2154.
 48 Wang H, taverna D, Stram DO, et al. genetic variation in the inflammation and 
innate immunity pathways and colorectal cancer risk. Can Epidemiol Biomark Prev 
2013;22:2094–101.
 49 couturier- Maillard a, Secher t, rehman a, et al. nod2- Mediated dysbiosis 
predisposes mice to transmissible colitis and colorectal cancer. J Clin Invest 
2013;177:700–11.
 50 robertson SJ, Zhou JY, geddes K, et al. nod1 and nOD2 signaling does not alter 
the composition of intestinal bacterial communities at homeostasis. Gut Microbes 
2013;4:222–31.
 51 Udden SMn, Peng l, gan J- l, et al. nod2 suppresses colorectal tumorigenesis via 
downregulation of the tlr pathways. Cell Rep 2017;19:2756–70.
 52 Snetselaar r, van Oosterhout MFM, grutters Jc, et al. telomerase reverse transcriptase 
polymorphism rs2736100: a balancing act between cancer and non- cancer disease, a 
meta- analysis. Frontiers in Medicine 2018;5.
 53 Pittman aM, naranjo S, Jalava Se, et al. allelic variation at the 8q23.3 colorectal 
cancer risk locus functions as a cis- acting regulator of eiF3H. PLoS Genet 
2010;6:e1001126.
 54 carvajal- carmona lg, cazier J- B, Jones aM, et al. Fine- Mapping of colorectal cancer 
susceptibility loci at 8q23.3, 16q22.1 and 19q13.11: refinement of association 
signals and use of in silico analysis to suggest functional variation and unexpected 
candidate target genes. Hum Mol Genet 2011;20:2879–88.
 55 grandval P, Blayau M, Buisine M- P, et al. the UMD- aPc database, a model of 
nation- wide knowledge base: update with data from 3,581 variations. Hum Mutat 
2014;35:532–6.
 56 lynch Ht, Snyder cl, Shaw tg, et al. Milestones of lynch syndrome: 1895–2015. Nat 
Rev Cancer 2015;15:181–94.
 o
n
 D
ecem
ber 12, 2019 at University of Edinburgh. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2019-319313 on 9 December 2019. Downloaded from 
